News archive search

Search the Newsreel

Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.

Showing
37–47
Matches
47
Sources here
1
Companies here
1
Search results Stored financial headlines

Active search

47 matching headlines

Ticker or company: ABBV34Main company stories
Clear

Search results

Matching headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

finance.yahoo.com Earnings Main company 🇧🇷 Brazil

AbbVie shares fall on earnings miss and weak guidance

Investing.com -- AbbVie Inc. (NYSE: ABBV) reported second-quarter earnings before the open on Friday, missing profit expectations, although revenue beat the consensus estimate. Adjusted earnings per share came in at $3.65, missing analyst estimates of $3.71, while revenue of $16.99 billion exceeded the consensus …

ABBV34 main company
Sharemaestro market context Trend signal active 52 weeks +16.4% ABBV34 stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Earnings Main company 🇧🇷 Brazil

What To Expect From AbbVie’s (ABBV) Q2 Earnings

What To Expect From AbbVie's (ABBV) Q2 Earnings Pharmaceutical company AbbVie (NYSE:ABBV) will be announcing earnings results this Friday before market hours. Here's what to look for. AbbVie beat analysts' revenue expectations last quarter, reporting revenues of $15 billion, up 12.4% year on year. …

ABBV34 main company
Sharemaestro market context Trend signal active 52 weeks +16.4% ABBV34 stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Regulatory and legal Main company 🇧🇷 Brazil

JUVÉDERM® Day Returns to U.S. on August 19

Allergan Aesthetics celebrates fourth annual JUVÉDERM®Day with buy-one-get-one (BOGO) gift cards and double points for Allē Members This summer marks the 20th anniversary of the brand's first U.S. Food and Drug Administration (FDA) dermal filler approval Join Allē today to take advantage of limited …

ABBV34 main company
Sharemaestro market context Trend signal active 52 weeks +16.4% ABBV34 stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Earnings Main company 🇧🇷 Brazil

AbbVie (ABBV) Stock May Be Mispriced On Its 172% Run

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. AbbVie stock has delivered strong returns over the past five years, yet the current …

ABBV34 main company
Sharemaestro market context Trend signal active 52 weeks +16.4% ABBV34 stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Regulatory and legal Main company 🇧🇷 Brazil

AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Non-Segmental Vitiligo

RINVOQ is the first and only systemic medication approved in the European Union to treat adult and adolescent patients with non-segmental vitiligo (NSV) The approval is supported by data from the Phase 3 Viti-Up clinical program, which showed that RINVOQ achieved statistically significant total …

ABBV34 main company
Sharemaestro market context Trend signal active 52 weeks +16.4% ABBV34 stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Deals and strategy Main company 🇧🇷 Brazil

Botox Maker Tops Buy Point, But Here Comes The Earnings Report

AbbVie closed above the 230.47 buy point from a cup-with-handle base on June 23 and has climbed 15% from there. The previous day, the stock jumped more than 6% after AbbVie announced it agreed to acquire Apogee Therapeutics. The $10.9 billion deal would strengthen …

ABBV34 main company
Sharemaestro market context Trend signal active 52 weeks +16.4% ABBV34 stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Earnings Main company 🇧🇷 Brazil

Should You Buy, Hold or Sell ABBV Stock Ahead of Q2 Earnings?

AbbVie ABBV is set to report second-quarter 2026 earnings on July 31, before the opening bell. The Zacks Consensus Estimate for the to-be-reported quarter's sales is pinned at $16.81 billion, while earnings per share (EPS) are estimated at $3.66. Both metrics indicate an increase …

ABBV34 main company
Sharemaestro market context Trend signal active 52 weeks +16.4% ABBV34 stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Earnings Main company 🇧🇷 Brazil

AbbVie (ABBV) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

The market expects AbbVie (ABBV) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2026. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence …

ABBV34 main company
Sharemaestro market context Trend signal active 52 weeks +16.4% ABBV34 stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Earnings Main company 🇧🇷 Brazil

How Investors May Respond To AbbVie (ABBV) Securing EU Approval For Short-Acting Boey Aesthetic Toxin

In July 2026, Allergan Aesthetics, an AbbVie company, received European Commission approval for Boey (trenibotulinumtoxinE), a rapid-onset, short-duration botulinum neurotoxin serotype E for adults with psychologically impactful moderate to severe glabellar lines, following similar approval in Canada. As the first approved serotype E neurotoxin …

ABBV34 main company
Sharemaestro market context Trend signal active 52 weeks +16.4% ABBV34 stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Earnings Main company 🇧🇷 Brazil

AbbVie (ABBV) Beats Stock Market Upswing: What Investors Need to Know

AbbVie (ABBV) closed at $256.18 in the latest trading session, marking a +1.11% move from the prior day. The stock's performance was ahead of the S&P 500's daily gain of 0.89%. Elsewhere, the Dow gained 0.74%, while the tech-heavy Nasdaq added 1.29%. Shares of …

ABBV34 main company
Sharemaestro market context Trend signal active 52 weeks +16.4% ABBV34 stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Earnings Main company 🇧🇷 Brazil

AbbVie (ABBV) Wins EU Approval For Boey Frown Line Treatment In Europe

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Allergan Aesthetics, an AbbVie company (NYSE:ABBV), received European Commission approval for Boey (trenibotulinumtoxinE). Boey is described as the first rapid onset, short duration …

ABBV34 main company
Sharemaestro market context Trend signal active 52 weeks +16.4% ABBV34 stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context